ResMed Inc. (RMD), a market leader in digital health services and medical equipment, has garnered significant interest from growth investors, primarily due to their innovative products, such as the smallest full-face CPAP mask, AirFit F40, and their digital health services. Besides, they retain a
‘Moderate Buy’ average consensus recommendation from brokerages. The company has reported better-than-expected Q2 and Q3 FY2024 earnings, indicating a strong growth trajectory. Its Q3 results exceeded analyst expectations, largely driven by solid revenue growth. What's more, ResMed stock has seen a substantial return of 101% over the last five years. It's experiencing robust growth, receiving widespread support from institutions, with institutional investors owning 61% of shares. Distinguished investors including Fiduciary Trust Co, Franklin Resources Inc, and others have increased their positions in ResMed. Even though certain headlines suggest recent drops in the stock's value, the company’s strong fundamentals, increasing demand for sleep devices, strong EPS growth, judicious use of debt, and capital investments point towards its promising future. ResMed appears undervalued in the intrinsic calculation, making it a favorite pick of growth investors.
Resmed RMD News Analytics from Mon, 11 Sep 2023 07:00:00 GMT to Sat, 01 Jun 2024 15:14:54 GMT -
